Should Baseline Characteristics Affect Treatment Choice for PDR?

In this interview from ASRS 2018, Dr. Susan Bressler discusses how patient baseline characteristics affect the outcomes of patients who are being treated with 2 proliferative diabetic retinopathy (PDR) treatments: ranibizumab and panretinal photocoagulation (PRP). None of the 25 patient characteristics that were assessed showed that PRP was superior to ranibizumab at 2 years. Instead, patients with high blood pressure or advanced PDR exhibited a greater improvement on ranibizumab, compared with PRP. According to Dr. Bressler, although PRP is still a good option, some patients may benefit more from regular anti-VEGF treatment over 2 years.

Relevant Financial Disclosures: Dr. Susan Bressler receives grant support from Genentech